The differential effects of prostaglandin E1 and nitroglycerin on regional cerebral oxygenation.
Spahn
D R
DR
D000527:Alprostadil / Q000008:administration & dosage / Q000627:therapeutic use*; D000771:Anesthesia, Intravenous; D018686:Anesthetics, Intravenous / Q000008:administration & dosage; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D005283:Fentanyl / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008874:Midazolam / Q000008:administration & dosage; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage; D005996:Nitroglycerin / Q000008:administration & dosage / Q000627:therapeutic use*; D010101:Oxygen Consumption / Q000187:drug effects*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014673:Vecuronium Bromide / Q000008:administration & dosage
D018686:Anesthetics, Intravenous; D003473:Neuromuscular Nondepolarizing Agents; D014665:Vasodilator Agents; D014673:Vecuronium Bromide; D000527:Alprostadil; D005996:Nitroglycerin; D008874:Midazolam; D005283:Fentanyl